ACS Omega
May 13, 2026
Darío Martínez-afani, Breno A. Soares, Jaime Mella-Raipán et al.
1 citation
High Resolution Image Download MS PowerPoint Slide Serotonin 5-HT 2 receptor ligands have attracted the attention of medicinal chemists for the last half-century, first as hallucinogens and later for their antipsychotic, appetite suppressant, antiaddictive and antidepressant potential. Unlike the very potent N -benzylphenethylamine derivatives that include the abundantly studied NBOMe drugs, N...
RSC Chem Biol
May 7, 2026
The working lives of neuronal 5-HT2A receptors from the outside in.
Journal of Psychopharmacology
May 2, 2026
Zarmeen Zahid, Rick J. Strassman, Clifford Qualls et al.
Serotonergic psychedelics are being investigated in the treatment of various disorders and in the improvement of well-being. Evidence suggests that their subjective effects may play a role in long-term behavioral outcomes. The subjective effects are mediated by 5-HT2A receptor agonism, but the 5-HT1A receptor may also play a role in the subjective effects. This study elucidates the effects of...
Neuroscience & Biobehavioral Reviews
May 1, 2026
Esmaeel G Gojani, Houman Farzin, Robert J Sutherland et al.
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder characterized by amyloid-β (Aβ) accumulation, tau pathology, synaptic dysfunction, and neuroinflammation, which collectively drive progressive memory loss, cognitive decline, and behavioral changes. Increasing evidence implicates epigenetic dysregulation as a key contributor to these pathological processes by altering gene...
American Journal of Respiratory and Critical Care Medicine
May 1, 2026
S Pack, Tyler R Ellett, Jamie Pham et al.
Abstract Introduction Ayahuasca is a psychoactive brew used in Amazonian ceremonies, containing monoamine oxidase inhibitors (MAOIs) from Banisteriopsis caapi and N,N-dimethyltryptamine (DMT) from Psychotria viridis or Diplopterys cabrerana. Its global use has expanded for perceived antidepressant and anti-addictive effects. However, its MAOI content predisposes users to serotonergic toxicity...
Molecular Psychiatry
May 1, 2026
Sixtine Fleury, Katherine M. Nautiyal
4 citations
Recent studies highlight the promising use of psychedelic therapies for psychiatric disorders, including depression. The persisting clinical effects of psychedelics such as psilocybin are commonly attributed to activation of the serotonin 2A receptor (5-HT2AR) based on its role in the acute hallucinatory effects. However, the active metabolite of psilocybin binds to many serotonin receptor...
International Journal of Drug Delivery Technology
April 30, 2026
Dr. Dheerendra Kumar, Dr. Praveen Sachan, Dr. Piyush Verma
Aim This study aims to compare two treatment procedures (standard selective serotonin reuptake inhibitors and rapid-acting therapies/specifically ketamine) for patients suffering from treatment-resistant depression along with evaluating the effectiveness of these approaches in alleviating symptoms and improving patient outcomes. Materials and Methods This study examined 80 patients suffering...
ACS Medicinal Chemistry Letters
April 27, 2026
Ram W. Sabnis, Anika R. Sabnis
Provided herein are novel indoline derivatives serotonergic psychedelic agents as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating psychosis, mental illness and central nervous system (CNS) disorders and processes for preparing such compounds.
International Journal For Multidisciplinary Research
April 22, 2026
Aparna Shukla, Shubhangi Chandrikapure
Hallucinations are perceptual disturbances occurring without external stimuli, commonly observed in psychiatric disorders such as schizophrenia and substance-induced psychosis. Dysregulation of monoaminergic neurotransmitters, particularly dopamine and serotonin, plays a central role in their pathophysiology. Dopaminergic hyperactivity in the mesolimbic pathway leads to aberrant salience...
bioRxiv : the preprint server for biology
April 21, 2026
Jeanine Yacoub, Elena Bray, Jude Bayyat et al.
preprint
Serotonergic psychedelics such as N,N-dimethyltryptamine (DMT) and 4-phosphoryloxy-N,N-dimethyltryptamine (psilocybin) show therapeutic promise for psychiatric and neurodegenerative disorders but may be limited by liabilities from serotonin (5-HT)-2A mediated psychoactive effects and potential cardiotoxicity via 5-HT2B activation. To address these limitations, we designed and synthesized...